Literature DB >> 10732740

No association between P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck.

N Hamel1, M J Black, P Ghadirian, W D Foulkes.   

Abstract

An initial report suggested that patients homozygous for the arginine allele at codon 72 of P53 were at increased risk for human papillomavirus (HPV)-related cervical cancer, but other groups have not confirmed this finding. Since approximately 18-36% of head and neck cancers are HPV-related, we examined the genotypic frequencies at that locus in 163 cases with squamous cell carcinoma of the head and neck (SCCHN) and 163 ethnically matched controls. We found no significant excess of arginine homozygotes in cases compared to controls (P= 0.50). No significant differences in allele frequencies were observed when the data were stratified by tobacco exposure or by cancer site. These findings suggest a limited role, if any, for this P53 polymorphism in SCCHN.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10732740      PMCID: PMC2374404          DOI: 10.1054/bjoc.1999.0993

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  13 in total

1.  Combined p53-related genetic variants together with HPV infection increase oral cancer risk.

Authors:  Zhongqiu Wang; Erich M Sturgis; Yang Zhang; Zhigang Huang; Qi Zhou; Qingyi Wei; Guojun Li
Journal:  Int J Cancer       Date:  2011-12-02       Impact factor: 7.396

2.  Association of p53 codon 72 polymorphism with risk of second primary malignancy in patients with squamous cell carcinoma of the head and neck.

Authors:  Fanglin Li; Erich M Sturgis; Xingming Chen; Mark E Zafereo; Qingyi Wei; Guojun Li
Journal:  Cancer       Date:  2010-05-15       Impact factor: 6.860

3.  p53 codon 72 polymorphism and risk of cervical carcinoma in Moroccan women.

Authors:  M Meftah El khair; M M Ennaji; R El kebbaj; R Ait Mhand; M Attaleb; M El Mzibri
Journal:  Med Oncol       Date:  2009-09-23       Impact factor: 3.064

4.  Effect of maternal Tp53 gene G412C polymorphism on neural tube defects: A study from North India.

Authors:  Jyoti Arora; Kallur N Saraswathy; Roumi Deb
Journal:  Indian J Hum Genet       Date:  2012-05

Review 5.  A review of genetic epidemiology of head and neck cancer related to polymorphisms in metabolic genes, cell cycle control and alcohol metabolism.

Authors:  G Cadoni; S Boccia; L Petrelli; P Di Giannantonio; D Arzani; A Giorgio; E De Feo; M Pandolfini; P Gallì; G Paludetti; G Ricciardi
Journal:  Acta Otorhinolaryngol Ital       Date:  2012-02       Impact factor: 2.124

6.  Association of p53 codon 72 polymorphism with advanced lung cancer: the Arg allele is preferentially retained in tumours arising in Arg/Pro germline heterozygotes.

Authors:  E D Papadakis; N Soulitzis; D A Spandidos
Journal:  Br J Cancer       Date:  2002-10-21       Impact factor: 7.640

7.  p53 polymorphisms associated with mutations in and loss of heterozygosity of the p53 gene in male oral squamous cell carcinomas in Taiwan.

Authors:  L-L Hsieh; T-H Huang; I-H Chen; C-T Liao; H-M Wang; C-H Lai; S-H Liou; J T-C Chang; A-J Cheng
Journal:  Br J Cancer       Date:  2005-01-17       Impact factor: 7.640

8.  Determination of p53 genotypes in oral cancer patients from India.

Authors:  A T Tandle; V Sanghvi; D Saranath
Journal:  Br J Cancer       Date:  2001-03-23       Impact factor: 7.640

9.  A case-control study on the combined effects of p53 and p73 polymorphisms on head and neck cancer risk in an Italian population.

Authors:  Paola Gallì; Gabriella Cadoni; Mariangela Volante; Emma De Feo; Rosarita Amore; Arianna Giorgio; Dario Arzani; Gaetano Paludetti; Gualtiero Ricciardi; Stefania Boccia
Journal:  BMC Cancer       Date:  2009-05-08       Impact factor: 4.430

10.  P53 gene codon 72 polymorphism in patients with oral squamous cell carcinoma in the population of northern Iran.

Authors:  Mahmud Sina; Mehrdad Pedram; Morteza Ghojazadeh; Ahmad Kochaki; Amirala Aghbali
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2014-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.